Douglas Ginas, DO
Family Practice · Albertville, ALNPI 1629059456
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 363 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 39 manufacturers reported payments, led by AbbVie at 30.0% of the total. Among family practice clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 363 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Gilead$350
- GSK$282
- AstraZeneca$280
- Indivior Inc.$200
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,536100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 123 | $1,660 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 79 | $1,063 |
| Gilead | 18 | $350 |
| GSK | 16 | $282 |
| AstraZeneca | 17 | $280 |
| Indivior Inc. | 8 | $200 |
| Pfizer | 12 | $191 |
| Novo Nordisk | 9 | $161 |
| Orexo US, Inc. | 10 | $136 |
| Eisai Inc. | 9 | $126 |
| Exact Sciences | 6 | $103 |
| Genentech USA, Inc. | 5 | $80 |
| Sanofi-aventis U.S. LLC | 5 | $74 |
| Lilly USA, LLC | 5 | $73 |
| Johnson & Johnson | 3 | $69 |
| Bayer | 3 | $61 |
| Lundbeck LLC | 3 | $61 |
| Antares Pharma, Inc. | 2 | $53 |
| Braeburn Inc. | 2 | $52 |
| Idorsia Pharmaceuticals US Inc | 3 | $47 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Boehringer Ingelheim | 2 | $36 |
| Biohaven Pharmaceuticals, Inc. | 2 | $34 |
| Dexcom, Inc. | 2 | $32 |
| Merck | 2 | $29 |
| UCB, Inc. | 2 | $27 |
| Almatica Pharma LLC | 1 | $25 |
| Alkermes, Inc. | 1 | $23 |
| Redhill Biopharma Inc. | 1 | $21 |
| Vertex | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Amgen | 1 | $16 |
| MDD US Operations, LLC | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Medtronic | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
| Adlon Therapeutics L.p. | 1 | $11 |
How this compares
$5,536 in reported general payments places this provider in the 95th percentile of 71 family practice providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 128 | $143,146 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 100 | $70,336 |
| MounjaroTirzepatide | 58 | $60,113 |
| JardianceEmpagliflozin | 42 | $40,004 |
| TrulicityDulaglutide | 28 | $26,142 |
| EliquisApixaban | 30 | $22,905 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 137 | $21,940 |
| EntrestoSacubitril/Valsartan | 22 | $17,716 |
| MyrbetriqMirabegron | 32 | $15,440 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $14,421 |
| FarxigaDapagliflozin Propanediol | 21 | $14,395 |
| RybelsusSemaglutide | 15 | $14,214 |
| LinzessLinaclotide | 21 | $13,898 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $9,812 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $9,365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $161 | $157,360143 claims |
| Lilly USA, LLCMounjaro, Trulicity | $73 | $86,25586 claims |
| GSKTrelegy Ellipta | $282 | $70,336100 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $36 | $45,46053 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $280 | $29,23560 claims |
| PfizerEliquis | $191 | $22,90530 claims |
| AbbVieLinzess, Synthroid | $1,660 | $15,14341 claims |
| MerckJanuvia | $29 | $7,54912 claims |
| Indivior Inc.Suboxone | $200 | $6,44713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 71 family practice providers in Alabama.
Other family practice in Albertville
- Stephen WinstonFairhope$5K
- Embril EdwardsGuntersville$4K
- Christopher JohnsonHuntsville$3K
- Jonah McIntyreAtmore$2K
- Adam AltermanRainbow City$545
- Katherine VintsonCullman$420
- Julia ToddHuntsville$150
- Rebecca ConwayHuntsville$118
- Jesse AustinMontgomery$53
- Laura SatcherHuntsville$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.